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PCR profiles were found in lesions and blood, but 1 case with a
mixed infection had Tc II in chagomas and allograft heart and Tc
I in blood. RA patients were treated with benznidazole with neg-
ative PCR results and remission of clinical manifestations, but in
one case a second RA occurred 286 days after end of treatment.
Conclusions: Both lineages are linked to myocarditis causing ChD,
revealing a higher frequency of Tc I than expected for the southern
cone of America. Tc II displayed higher parasitemias than Tc I. Dif-
ferential histotropism occurred in pts with mixed infections. This
study also underlines the value of PCR for early diagnosis of RA and
monitoring of treatment efficacy.
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Ex-vivo Respiratory Burst Response to S. cerevisae after
Lung Transplantation
Charulata Ramaprasad, Randee Estes, Sangeeta Bhorade,
David Pitrak. The University of Chicago Hospitals, Department of
Internal Medicine, Chicago, USA
Background: Lung transplant recipients are at risk for opportunis-
tic infections as a result of potent immunosuppression targeting
cell-mediated immunity. However, neutropenia or neutrophil dys-
function is the main risk factor for many of the infections these
patients contract, including serious bacterial and invasive fungal
infections. We hypothesize that neutrophil function, as measured
by neutrophil respiratory burst (RB), is significantly decreased in
lung transplant recipients.
Materials/Methods: Fourteen lung transplant patients undergoing
routine phlebotomy were enrolled. Neutrophils were isolated from
the blood of patients and controls, brought to a standard concen-
tration of 1x107 cells per milliliter (mL), and stimulated with op-
sonized zymosan particles. Reaction mixtures of 100 microliters of
zymosan and neutrophil suspension and 500 microliters of lumi-
nol were analyzed with a luminometer. The amount of light given
off (chemiluminescence, CL), which is directly proportional to the
neutrophil RB per cell, was measured.
Results: Sixteen patient samples from 14 patients were tested (two
patients were tested twice). A control sample was evaluated with
each patient sample. One patient' s data was excluded, thus 15
patient samples from 14 separate patients were analyzed. Lung
transplant recipients had lower mean CL than controls (3.37x109
vs. 4.03x109). This difference was not statistically significant. 9/15
patient samples had normal CL values when compared to controls.
6/15 patient samples had CL values that were more than 1 stan-
dard deviation (SD) below the mean CL value for controls (Fisher' s
Abstract 26 – Figure 1. Enrollment schematic and respitarory burst results for lung transplant recipients.
Figure 2. Percentage of lung transplant recipients with normal and
decreased respiratory burst.
Exact Test, p=0.046). In fact, 3 of these 6 patient samples had CL
values that were more than 2 SD below this same mean, indicat-
ing severely decreased super-oxide production and RB capacity. All
6 patients with low CL values had no change in their risk of con-
current infection or rejection. There was no correlation between
CL and time from transplant, absolute neutrophil count, or T-cell
function, indicating that this test may be useful as an independent
marker of immune function.
Conclusions: Lung transplant recipients vary considerably with re-
spect to their RB capacity. Some patients have RB defects com-
parable to the defects seen in Chronic Granulomatous Disease of
Childhood, a disease characterized by low super-oxide production
and high rates of infection. Further studies are needed to evaluate
the role that RB defects play in infectious risk for this population.
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Absence of BK Viremia Clearance after Low-dose Cidofovir
Therapy in Kidney Transplant Recipients with BK Virus
Associated Nephropathy
Frédéric Lamoth, Manuel Pascual, Ghaleb Nseir, Jean-Pierre
Venetz, Pascal R. Meylan.. Centre Hospitalier Universitaire
Vaudois and University of Lausanne, Service of Infectious Diseases
and Transplantation Centre, Lausanne, Switzerland
Background: BK virus associated nephropathy occurs in 1-10% of
kidney transplant recipients and may be a cause of graft loss. This
infection is difficult to manage because of the absence of specific
therapy. Cidofovir, a DNA polymerase inhibitor approved for the
treatment of CMV retinitis, has shown in vitro activity against BK
virus and some clinical efficacy when used at low-dose in uncon-
trolled series.
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Objective: To assess the efficacy of low-dose Cidofovir in the treat-
ment of BK virus associated nephropathy.
Method: Two adult kidney transplant recipients with biopsy-proven
BK nephropathy and persistent high viremia (>10,000 copies/ml)
despite 3-month reduction of immunosuppressive therapy were
treated by Cidofovir 0.5 mg/kg fortnightly for a total of 16 weeks
(8 doses). Clinical response was assessed by following BK viremia.
Results: No decrease in BK viremia was observed at any point dur-
ing cidofovir therapy (see figure). Creatinine clearance remained
stable during therapy and no side-effects of Cidofovir were ob-
served.
Conclusions: Low-dose Cidofovir therapy was not associated with
a clearance or with a significant decrease of BK viremia. This pilot
study does not confirm previous reports suggesting clinical efficacy
of Cidofovir for BK virus associated nephropathy.
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No Detectable Indirect Effects of Late-onset
Cytomegalovirus Disease after Valganciclovir (VGC)
Prophylaxis in Kidney Transplant Recipients.
Frédéric Lamoth, Oriol Manuel, Pascal R. Meylan,
Jean-Pierre Venetz, Mohammed Faouzi, Manuel Pascual. Centre
Hospitalier Universitaire Vaudois and University of Lausanne,
Service of Infectious Diseases and Transplantation Centre,
Lausanne, Switzerland
Background: Cytomegalovirus (CMV) disease remains an important
cause of morbidity after kidney transplantation and has been asso-
ciated with acute rejection, graft loss and other indirect effects.
A 3-month course of VGC prophylaxis reduces the incidence of CMV
disease. However, little is known about the indirect effects of late-
onset CMV disease after VGC prophylaxis.
Objective: To evaluate the impact and indirect consequences of
late-onset CMV disease after VGC prophylaxis in kidney transplant
recipients.
Methods: Retrospective analysis of 61 consecutive adult kidney
transplant recipient with positive CMV serology (donor or recipi-
ent) who received VGC prophylaxis for 3 months and completed
a follow-up of at least 2 years post-transplantation. Patients who
developed CMV disease within 1 year after transplantation were
compared to CMV disease-free patients for renal function (plasma
creatinine values) at 1, 6, 12 and 24 months and for the incidence
of graft loss, acute rejection, diabetes, cancer and opportunistic
infections.
Results: 8/61 (13%) patients developed CMV disease at a median of
131 days after transplantation (range: 98–220). The CMV incidence
in D+/R- high risk patients was 6/18 (33%), while it was 2/43 (5%) in
intermediate-risk patients (p < 0.01). All 8 patients were treated
by oral valganciclovir (median 39 days; range: 19–119) with a com-
plete resolution of CMV disease. As shown in the figure, there was
no difference in creatinine values between the two groups at any
time during follow-up. There was no graft loss, and the incidence
of acute rejection, cancer and opportunistic infections did not dif-
fer between the two groups. The incidence of post-transplant di-
abetes was higher (38% vs 15%) in patients with CMV disease, but
this difference was not significant (p = 0.4).
Conclusions: An incidence of 13% of late-onset CMV disease was
observed despite 3 months VGC prophylaxis. However, no indirect
consequences were found. Moreover, therapy of CMV disease by
oral VGC was effective and safe. Larger trials are needed to study
whether late-onset CMV disease is associated with indirect conse-
quences, as described with early-onset CMV.
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BKV Viral Load Monitoring and Leflunomide Treatment in
Renal Transplant Recipients
Eirini Grispou1, Eirini Sinodinou2, Mary Anagnostopoulou1,
Kimon Foudoulis1, Ioannis Boletis2, Olga Paniara1. 1Microbiology
Department, Evaggelismos General Hospital, Athens, Greece;
2Transplant Unit of Laiko Hospital, Athens, Greece
Background: BKV associated nephropathy is a major problem
among renal transplant recipients as it leads to graft loss. Iden-
tification and monitoring of high risk patients is crucial for the
induction of therapy and the survival of the graft.
Objectives: We examine the effectiveness of quantitative Real-
Time PCR to identify patients at high risk of BKVN and monitor the
efficacy of treatment, in order to avoid invasive methods.
Methods: From 7/2005 to 2/2008 231 paired samples (plasma and
urine) were sent to our lab for BKV viral load measurement. The
samples were drawn upon kidney dysfunction from 121 patients
that underwent renal transplantation at the transplant unit of
Laiko Hospital. On the basis of PCR positivity the patients were
classified into 3 groups. Group 1 (n=89) tested negative both in
plasma and urine. In Group 2 (n=22) BKV DNA was detected only in
urine while Group 3 patients (n=10) had DNAemia and viruria and
were treated with leflunomide along with reduction of immuno-
suppression.
Results: Group 1 and Group 2 patients never developed BKVN.
Group 2 patients had a median viral load of 2.6×104 copies/mL,
but had negative urine cytopathology or biopsy. Group 3 me-
dian viral load of DNAemia and viruria was respectively 3.9×104
copies/mL and 7.15×104 copies/mL. 80% of the patients had posi-
tive urine cytopathology and 100% had positive biopsy.
Upon treatment with leflunomide DNAemia resolved very quickly,
while viruria showed clearance or progressive reduction in 80%.
Two patients that showed multiple reactivations of the virus even-
tually resolved as well.
Conclusions: Viral load measurement in paired plasma and urine
samples is a sensitive and specific non invasive method for the
monitoring of BKV infection in RT recipients. Since the incidence of
